Mining and analysis of adverse drug events signals of nilotinib based on FDA adverse event database
- VernacularTitle:基于FAERS数据库对尼洛替尼ADE信号的挖掘与分析
- Author:
Hui SU
1
;
Tingting JIANG
1
;
Ni ZHANG
1
;
Yanping LI
1
;
Yongqing CAI
1
;
Dan PENG
1
;
Yao LIU
1
Author Information
1. Dept. of Pharmacy，Army Medical Center of the PLA，Chongqing 400042，China
- Publication Type:Journal Article
- Keywords:
US FDA adverse event reporting system database;
nilotinib;
adverse drug event;
signal mining;
disproportionality
- From:
China Pharmacy
2023;34(21):2625-2630
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide a reference for safe drug use in clinic. METHODS ADE reports related to nilotinib from the first quarter of 2007 to the fourth quarter of 2022 were collected from the US FDA adverse event reporting system database. The reporting odds ratio （ROR） and proportional reporting ratio （PRR） of disproportionality measures were used to mine potential ADE signals，which were compared with drug instruction and related case report， and were screened and analyzed according to the designated medical events （DME） list formulated by the European Medicines Agency. RESULTS Totally 23 332 cases of ADE with nilotinib as the primary suspected drug were reported. A total of 359 positive signals were obtained，involving 24 system organ classes （SOC），mainly concentrated in various examinations，heart organ diseases，vascular and lymphatic diseases，all kinds of nervous system diseases，etc. Among them，ADEs such as vertebral artery stenosis，coronary artery stenosis，arterial disease，liver infection and the second primary malignant tumor were not mentioned in the instructions. Seven DMEs were detected，of which bone marrow failure，pulmonary hypertension and deafness were not mentioned in the drug instruction. CONCLUSIONS The common ADE signals of nilotinib excavated in this study are consistent with the instructions. In clinical use，special attention should be paid to DME not mentioned in the instructions such as bone marrow failure，pulmonary hypertension and deafness； cardiac function， blood glucose and blood lipid indexes should be monitored closely.
